Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 1
2007 1
2008 1
2009 3
2010 1
2011 2
2012 1
2013 1
2014 1
2015 1
2016 1
2017 5
2018 5
2019 2
2020 5
2021 6
2022 12
2023 18
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial.
Song Y, Tilly H, Rai S, Zhang H, Jin J, Goto H, Terui Y, Shin HJ, Kim WS, Cao J, Feng J, Eom HS, Kim TM, Tsai XC, Gau JP, Koh H, Zhang L, Song Y, Yang Y, Li W, Huang H, Ando K, Sharman JP, Sehn LH, Bu L, Wang X, Jiang Y, Hirata J, Lee C, Zhu J, Izutsu K. Song Y, et al. Among authors: goto h. Blood. 2023 Apr 20;141(16):1971-1981. doi: 10.1182/blood.2022017734. Blood. 2023. PMID: 36626583 Free PMC article. Clinical Trial.
A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.
Terui Y, Rai S, Izutsu K, Yamaguchi M, Takizawa J, Kuroda J, Ishikawa T, Kato K, Suehiro Y, Fukuhara N, Ohmine K, Goto H, Yamamoto K, Kanemura N, Ueda Y, Ishizawa K, Kumagai K, Kawasaki A, Saito T, Hashizume M, Shibayama H. Terui Y, et al. Among authors: goto h. Cancer Sci. 2021 Jul;112(7):2845-2854. doi: 10.1111/cas.14937. Epub 2021 Jun 4. Cancer Sci. 2021. PMID: 33942442 Free PMC article. Clinical Trial.
Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma.
Ishio T, Kumar S, Shimono J, Daenthanasanmak A, Dubois S, Lin Y, Bryant B, Petrus MN, Bachy E, Huang DW, Yang Y, Green PL, Hasegawa H, Maeda M, Goto H, Endo T, Yokota T, Hatanaka KC, Hatanaka Y, Tanaka S, Matsuno Y, Yang Y, Hashino S, Teshima T, Waldmann TA, Staudt LM, Nakagawa M. Ishio T, et al. Among authors: goto h. Blood. 2022 Mar 10;139(10):1541-1556. doi: 10.1182/blood.2021012734. Blood. 2022. PMID: 34818414 Free PMC article.
Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas.
Chiba M, Shimono J, Ishio T, Takei N, Kasahara K, Ogasawara R, Ara T, Goto H, Izumiyama K, Otsuguro S, Perera LP, Hasegawa H, Maeda M, Hashino S, Maenaka K, Teshima T, Waldmann TA, Yang Y, Nakagawa M. Chiba M, et al. Among authors: goto h. Blood. 2022 Nov 3;140(18):1951-1963. doi: 10.1182/blood.2022015646. Blood. 2022. PMID: 35921533 Free PMC article.
Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort.
Ri M, Suzuki K, Ishida T, Kuroda J, Tsukamoto T, Teshima T, Goto H, Jackson CC, Sun H, Pacaud L, Fujikawa E, Yeh TM, Hatayama T, Aida K, Sunagawa Y, Iida S. Ri M, et al. Among authors: goto h. Cancer Sci. 2022 Dec;113(12):4267-4276. doi: 10.1111/cas.15556. Epub 2022 Oct 7. Cancer Sci. 2022. PMID: 36052883 Free PMC article. Clinical Trial.
Clinical implications of NUP98::NSD1 fusion at diagnosis in adult FLT3-ITD positive AML.
Miyajima T, Onozawa M, Yoshida S, Miyashita N, Kimura H, Takahashi S, Yokoyama S, Matsukawa T, Goto H, Sugita J, Fujisawa S, Hidaka D, Ogasawara R, Mori A, Matsuoka S, Shigematsu A, Wakasa K, Kasahara I, Saga T, Hashiguchi J, Takeda Y, Ibata M, Yutaka T, Fujimoto K, Kondo T, Teshima T. Miyajima T, et al. Among authors: goto h. Eur J Haematol. 2023 Oct;111(4):620-627. doi: 10.1111/ejh.14055. Epub 2023 Jul 19. Eur J Haematol. 2023. PMID: 37465857
69 results